← All trials
NCT05950061
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 1, 2022
- Primary completion
- Oct 29, 2022
- Completion date
- Feb 26, 2023
- First posted
- Jul 18, 2023
- Last posted
- Jul 18, 2023
- Enrollment
- 744
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- KRL Hospital, IslamabadLead sponsor
- Dow University of Health SciencesCollaborator
- Khyber Medical University PeshawarCollaborator
- KRL Hospital, IslamabadReponsible party - principal investigator
- KRL Hospital, IslamabadStudy director
- KRL Hospital, IslamabadOfficial
- KRL Hospital, IslamabadSponsor investigator
- Quaid-e-Azam Medical CollegeCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.